Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
01 août 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for...
Advances in Cancer Immunotherapy: Breakthrough Techniques and Key Players Explored in New Report
21 juil. 2023 04h53 HE
|
Research and Markets
Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including...
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
28 juin 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.
26 juin 2023 08h01 HE
|
Ocean Biomedical, Inc.
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in multiple...
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
26 juin 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’s Board of Directors (Board) to seek...
Global Breast Cancer Immunotherapy Market Size & Trends
20 juin 2023 10h08 HE
|
Global Market Estimates
Brooklyn, New York, June 20, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Breast Cancer Immunotherapy Market is projected to...
Global Immuno-Oncology Thematic Intelligence Report 2023: Focus on Trends in Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Checkpoint Modulators, Cytokines, & Oncolytic Viruses
13 juin 2023 04h48 HE
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Thematic Intelligence" report has been added to ResearchAndMarkets.com's offering.This report includes coverage of immuno-oncology...
Global STAT3 Inhibitors Market & Clinical Trials Outlook Report 2023-2028: Insights by Country, Indication, Organization & Phase
02 juin 2023 05h03 HE
|
Research and Markets
Dublin, June 02, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
30 mai 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 ...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
25 mai 2023 17h00 HE
|
Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...